Package Leaflet: Information for the User
Dupixent 200 mg solution for injection in pre-filled pen
dupilumab
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is Dupixent
Dupixent contains the active substance dupilumab.
Dupilumab is a monoclonal antibody (a special type of protein) that blocks the action of proteins called interleukins (IL)-4 and IL-13. Both play a key role in the appearance of signs and symptoms of atopic dermatitis and asthma.
What is it used for
Dupixent is used to treat adults and adolescents from 12 years of age with moderate to severe atopic dermatitis, also known as atopic eczema. Dupixent is also used to treat children from 6 months to 11 years of age with severe atopic dermatitis (see section Children and adolescents). Dupixent can be used with medicines for eczema that are applied to the skin or can be used alone.
Dupixent is also used, along with other asthma medicines, for the maintenance treatment of severe asthma in adults, adolescents, and children from 6 years of age whose asthma is not controlled with their current medication (e.g., corticosteroids).
How Dupixent works
Using Dupixent for atopic dermatitis (atopic eczema) may improve your skin disease and reduce itching. Dupixent has also shown an improvement in symptoms of pain, anxiety, and depression associated with atopic dermatitis. Additionally, Dupixent helps improve sleep disorders and your overall quality of life.
Dupixent helps prevent severe asthma attacks (exacerbations) and may improve your breathing ability. Dupixent may also help reduce the amount of another group of medicines you need to control your asthma, called oral corticosteroids, while preventing severe asthma attacks and improving your breathing ability.
Do not use Dupixent
If you think you may be allergic or are not sure, consult your doctor, pharmacist, or nurse before using Dupixent.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting Dupixent:
Dupixent is not a rescue medicineand should not be used to treat a sudden asthma attack.
Each time you have a new pack of Dupixent, it is important that you note the name of the medicine, the administration date, and the batch number (which is found on the packaging after "Batch") and keep this information in a safe place.
Allergic reactions
Eosinophilic diseases
Parasitic infection (intestinal parasites)
Asthma
If you have asthma and are taking asthma medication, do not change or stop taking your asthma medication without consulting your doctor. Consult your doctor before stopping treatment with Dupixent or if your asthma is not controlled or worsens during treatment with this medicine.
Eye problems
Consult your doctor if eye problems appear or worsen, including eye pain or changes in vision.
Children and adolescents
Other medicines and Dupixent
Tell your doctor or pharmacist
Other asthma medicines
Do not stop or reduce your asthma medicines unless your doctor tells you to.
Pregnancy and breastfeeding
Driving and using machines
It is unlikely that Dupixent will affect your ability to drive and use machines.
Dupixent contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per 200 mg dose; this is essentially "sodium-free".
Dupixent contains polysorbate
This medicine contains 2.28 mg of polysorbate 80 in each 200 mg dose (1.14 ml). Polysorbates may cause allergic reactions. Inform your doctor if you or your child have any known allergies.
Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If you are in doubt, consult your doctor or pharmacist again.
What dose of Dupixent you will receive
Your doctor will decide what dose of Dupixent is suitable for you.
Recommended dose in adolescents with atopic dermatitis
The recommended dose of Dupixent for adolescents (from 12 to 17 years of age) with atopic dermatitis is based on body weight:
Patient's body weight | Initial dose | Subsequent doses (every 2 weeks) |
less than 60 kg | 400 mg (two 200 mg injections) | 200 mg |
60 kg or more | 600 mg (two 300 mg injections) | 300 mg |
Recommended dose in children from 6 to 11 years of age with atopic dermatitis
The recommended dose of Dupixent for children (from 6 to 11 years of age) with atopic dermatitis is based on body weight:
Patient's body weight | Initial dose | Subsequent doses |
15 kg to less than 60 kg | 300 mg (one 300 mg injection) on day 1, followed by 300 mg on day 15 | 300 mg every 4 weeks*, starting 4 weeks after the day 15 dose |
60 kg or more | 600 mg (two 300 mg injections) | 300 mg every 2 weeks |
Recommended dose in children from 6 months to 5 years of age with atopic dermatitis
The recommended dose of Dupixent for children from 6 months to 5 years of age with atopic dermatitis is based on body weight:
Patient's body weight | Initial dose | Subsequent doses |
5 kg to less than 15 kg | 200 mg (one 200 mg injection) | 200 mg every 4 weeks |
15 kg to less than 30 kg | 300 mg (one 300 mg injection) | 300 mg every 4 weeks |
Recommended dose in adult and adolescent patients with asthma (from 12 years of age)
For most patients with severe asthma, the recommended dose of Dupixent is:
For patients with severe asthma who are taking oral corticosteroids or for patients with severe asthma and moderate to severe atopic dermatitis or adults with severe chronic rhinosinusitis with nasal polyps, the recommended dose of Dupixent is:
Recommended dose in children with asthma
The recommended dose of Dupixent for children (from 6 to 11 years of age) with asthma is based on body weight:
Patient's body weight | Initial and subsequent doses |
15 kg to less than 30 kg | 300 mg every 4 weeks |
30 kg to less than 60 kg | 200 mg every 2 weeks or 300 mg every 4 weeks |
60 kg or more | 200 mg every 2 weeks |
For patients from 6 to 11 years of age with asthma and severe atopic dermatitis, your doctor will decide what dose of Dupixent is suitable for you.
Dupixent injection
Dupixent is administered by injection under your skin (subcutaneous injection). You and your doctor or nurse should decide if you should inject Dupixent yourself.
Before injecting Dupixent yourself, you must have been properly trained by your doctor or nurse. Your Dupixent injection can also be administered by a caregiver after proper training by a doctor or nurse. Each pre-filled pen contains a dose of Dupixent (200 mg). Do not shake the pre-filled pen. Read the "Instructions for Use" carefully included at the end of the package leaflet before using Dupixent.
If you use more Dupixent than you should
If you use more Dupixent than you should or have been administered the dose too soon, consult your doctor, pharmacist, or nurse.
If you forget to use Dupixent
If you have forgotten to inject a dose of Dupixent, consult your doctor, pharmacist, or nurse.
Additionally,
If your dosing schedule is every weekand you miss a dose of Dupixent:
If your dosing schedule is every 2 weeksand you miss a dose of Dupixent:
If your dosing schedule is every 4 weeksand you miss a dose of Dupixent:
If you stop treatment with Dupixent
Do not stop treatment with Dupixent without discussing it with your doctor first.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Dupixent may cause serious side effects, including rare allergic reactions (hypersensitivity), including anaphylactic reaction, serum sickness, serum sickness-like reaction; the signs may include:
If you develop an allergic reaction, stop using Dupixent and consult your doctor immediately.
Other side effects
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Additional side effects in children from 6 to 11 years of age with asthma
Common: worms (enterobiasis)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the pre-filled pen in the original package to protect it from light.
If necessary, the pre-filled pen can be removed from the refrigerator and stored in the carton at room temperature up to 25°C for a maximum of 14 days. The date it is removed from the refrigerator will be noted on the space provided on the outer carton. The carton should be discarded if it is left out of the refrigerator for more than 14 days or if it has passed the expiry date.
Do not use this medicine if you notice that the medicine is cloudy, discolored, or contains particles.
Medicines should not be disposed of via wastewater or household waste. Ask your doctor, pharmacist, or nurse how to dispose of medicines no longer required. This will help protect the environment.
Dupixent Composition
Product Appearance and Container Contents
Dupixent is a clear to slightly opalescent, colorless to pale yellow solution presented in a pre-filled pen.
The pre-filled pen may either have a round cap and an oval viewing window surrounded by an arrow, or it may have a square cap with edges and an oval viewing window without an arrow. Although there are small differences in the appearance of the two pre-filled pens, both function equally.
Dupixent is available as 200 mg pre-filled pens in a container containing 1, 2, or 6 pre-filled pens or in a container containing 6 (2 packs of 3) pre-filled pens.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Manufacturer
SANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel,
76580 LE TRAIT,
FRANCE Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 Industriepark Hoechst 65926 FRANKFURT AM MAIN GERMANY
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Sanofi Belgium Tel: +32 (0)2 710 54 00 | Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Luxembourg/Luxemburg Sanofi Belgium Tel: +32 (0)2 710 54 00 (Belgique/Belgien) | |
Ceská republika Sanofi, s.r.o. Tel: +420 233 086 111 | Magyarország SANOFI-AVENTIS Zrt. Tel.: +36 1 505 0050 |
Danmark Sanofi A/S Tlf: +45 45 16 70 00 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 04 36 996 Tel. from abroad: +49 69 305 70 13 | Nederland Sanofi B.V. Tel: + 31 20 245 4000 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Norge sanofi-aventis Norge AS Tlf: +47 67 10 71 00 |
Ελλάδα Sanofi-Aventis Μονοπρ?σωπη AEBE Τηλ: +30 210 900 16 00 | Österreich sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Polska Sanofi Sp. z o.o. Tel.: +48 22 280 00 00 |
France Sanofi Winthrop Industrie Tél: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 |
Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800 536389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 |
Κύπρος C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom(Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
--------------------------------------------------------------------------------------------------------------------
Dupixent 200 mg solution for injection in pre-filled pen
dupilumab
Instructions for use
This drawing shows the parts of the Dupixent pre-filled pen.
Important information
This device is a single-use pre-filled pen. It contains 200 mg of Dupixent for injection under the skin (subcutaneous injection).
Do not attempt to administer the injection to yourself or another person unless you have been trained by your healthcare professional. In adolescents from 12 years of age, it is recommended that Dupixent be administered by or under the supervision of an adult. In children under 12 years of age, Dupixent should be administered by a caregiver. The Dupixent pre-filled pen is for use in adults and children over 2 years of age only.
Storage of Dupixent
A: Prepare
A1. Prepare the necessary materials
Make sure you have the following:
A2. Check the label
A3. Check the expiration date
Do not use the pre-filled pen if the expiration date has passed.
Do not store Dupixent at room temperature for more than 14 days.
A4. Check the medication
Look at the medication through the pre-filled pen window.
Check that the liquid is clear and colorless to pale yellow.
Note: You may see an air bubble, but this is normal.
Do not use the pre-filled pen if the liquid is cloudy or discolored, or if it contains visible flakes or particles.
Do not use the pre-filled pen if the window is yellow.
A5. Wait 30 minutes
Place the pre-filled pen on a flat surface and let it warm up to room temperature (less than 25 °C) for at least 30 minutes.
Do not heat the pre-filled pen in a microwave, hot water, or direct sunlight.
Do not expose the pre-filled pen to direct sunlight.
Do not store Dupixent at room temperature for more than 14 days.
B1. Recommended injection sites are:
Choose a different injection site for each Dupixent injection.
Do not inject through clothing.
Do not inject into sensitive, damaged, or scarred skin.
B2. Wash your hands
B3. Prepare the injection site
Do not touch the injection site or blow on it before the injection.
C1. Remove the yellow cap
Pull the yellow cap straight off.
Do nottwist the yellow cap.
Do notremove the yellow cap until you are ready to inject.
Do notpress or touch the orange needle shield with your fingers. The needle is inside.
Do not put the yellow cap back on the pre-filled pen after it has been removed.
C2. Pinch the skin and place
Do not press or touch the orange needle shield with your fingers. The needle is inside.
C3. Press down
Press the pre-filled pen firmly against your skin until you can no longer see the orange needle shield and hold it there.
The injection may take up to 20 seconds.
No pinching is necessary in adults and children over 12 years of age.
C4. Hold firmly
Continue to hold the pre-filled pen firmly against your skin.
If the window does not turn completely yellow, remove the pre-filled pen and call your healthcare professional.
Do not administer a second dose without talking to your healthcare professional.
No pinching is necessary in adults and children over 12 years of age.
C5. Remove
Do not rub your skin after the injection.
Do notthrow away the pre-filled pens (needle inside) and yellow caps in the trash.
Do not put the yellow cap back on.
Dupixent 200 mg solution for injection in pre-filled pen
dupilumab
Instructions for use
This drawing shows the parts of the Dupixent pre-filled pen.
Important information
This device is a single-use pre-filled pen. It contains 200 mg of Dupixent for injection under the skin (subcutaneous injection).
Do not attempt to administer the injection to yourself or another person unless you have been trained by your healthcare professional. In adolescents from 12 years of age, it is recommended that Dupixent be administered by or under the supervision of an adult. In children under 12 years of age, Dupixent should be administered by a caregiver. The Dupixent pre-filled pen is for use in adults and children over 2 years of age only.
Storage of Dupixent
A: Prepare
A1. Prepare the necessary materials
Make sure you have the following:
A2. Check the label
A3. Check the expiration date
Do not use the pre-filled pen if the expiration date has passed.
Do not store Dupixent at room temperature for more than 14 days.
A4. Check the medication
Look at the medication through the window of the pre-filled pen.
Check that the liquid is clear and colorless to pale yellow.
Note: You may see an air bubble, but this is normal.
Do not use the pre-filled pen if the liquid is cloudy or discolored, or if it contains visible flakes or particles.
Do not use the pre-filled pen if the window is yellow.
A5. Wait 30 minutes
Place the pre-filled pen on a flat surface and let it warm up to room temperature (less than 25 °C) for at least 30 minutes.
Do not heat the pre-filled pen in a microwave, hot water, or direct sunlight.
Do notexpose the pre-filled pen to direct sunlight.
Do not store Dupixent at room temperature for more than 14 days.
B1. The recommended injection sites are:
Choose a different injection site for each Dupixent injection.
Do notinject through clothing.
Do notinject into sensitive, damaged, or scarred skin.
B2. Wash your hands
B3. Prepare the injection site
Do nottouch the injection site or blow on it before the injection.
C1. Remove the yellow cap
Pull the yellow cap straight off.
Do nottwist the yellow cap.
Do notremove the yellow cap until you are ready to inject.
Do notpress or touch the orange needle cover with your fingers. The needle is inside.
Do notput the yellow cap back on the pre-filled pen after it has been removed.
C2. Pinch the skin and place
Do notpress or touch the orange needle cover with your fingers. The needle is inside.
C3. Press down
Press the pre-filled pen firmly against your skin until the orange needle cover is no longer visible and hold it in place.
The injection may take up to 15 seconds.
Pinching is not necessary for adults and children over 12 years of age.
C4. Hold firmly
Continue to hold the pre-filled pen firmly against your skin.
If the window does not turn completely yellow, remove the pen and call your healthcare professional.
Do notadminister a second dose without talking to your healthcare professional.
Pinching is not necessary for adults and children over 12 years of age.
C5. Remove
Do notrub the skin after the injection.
Do notthrow away the pre-filled pens (with the needle inside) and the yellow caps in the trash.
Do notput the yellow cap back on.